Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 192 participants.

Also called NCT02066662

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose basic science
Phase
Phase 4
Enrolled
  • 192 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02066662
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02066662. Randomized; single masking; primary purpose basic science. Start 2013-07 (registry gives no type); primary completion 2020-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification
Condition
Need of Long Term Oral Anticoagulation Therapy (OAT)
Condition
Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location
Intervention (Drug)
Rivaroxaban or Marcumar
Lead sponsor
RWTH Aachen University (class: other)
Collaborator
Bayer (class: industry)

Record details

Record id
cardio:ct-nct02066662
Content hash
ad7deb9a9ce07874955dc5e05109b3289f8f22e0b8ffd6a512fae10a7b53ae06